1 Min Read
May 25 (Reuters) - Ionis Pharmaceuticals Inc
* Reports phase 1/2 clinical study results with AKCEA-ANGPTL3-L
* Says AKCEA-ANGPTL3-L was well tolerated with no serious adverse events Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.